Background: Currently, trimethoprim-sulfamethoxazole is used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis, but it is associated with frequent adverse effects. This study evaluated the efficacy and safety of the current protocol and proposes an individualized risk-based prophylaxis protocol.
INTRODUCTION
Pneumocystis jirovecii causes opportunistic respiratory infections in immunocompromised hosts (1) . The importance of P. jirovecii pneumonia (PJP) in solid organ transplant patients has been increasingly recognized over the past three decades owing to its increasing incidence. Without prophylaxis, 4% to 16% of patients experience PJP after renal transplantation. Although the mortality rate has improved greatly from 50% in 1990s, about 14% of renal transplant patients die owing to PJP (2) . Currently, universal prophylaxis is recommended after all solid organ transplantations, including renal transplantation (3) .
The first-line agent for PJP prevention is trimethoprim-sulfamethoxazole (TMP-SMX). After solid organ transplantation, guidelines recommend administering 80/400 mg daily TMP-SMX or 160/800 mg thrice a week (3) (4) (5) .
Although TMP-SMX is highly effective in preventing PJP (6) , it is far from ideal. Given the high rate of adverse reactions, TMP-SMX is frequently discontinued during therapy. Mitsides et al. (7) reported that 38% of renal transplant recipients experienced adverse reaction after TMP-SMX administration, leading to its discontinuation. Another controversial issue regarding PJP prophylaxis in renal allograft recipients is the therapy duration. While the European Renal Association recommends at least 4 months of prophylaxis after transplantation, 3 to 6 months are recommended in the Kidney Disease Improving Global Outcomes guideline (4, 5) . The latest guideline from the American Society of Transplantation recommends 6 to 12 months of prophylaxis for all solid organ transplant recipients (3) . Recent recommendations of prolonged prophylaxis stem from data showing increased risk of infection after completing prophylaxis, especially within 2 years post-transplantation (8) .
PJP outbreaks even years after transplantation have also been increasingly reported worldwide (9) . Hence, considering the high PJP-associated mortality and morbidity, some even advocate lifelong prophylaxis (10) . However, considering the aforementioned adverse reactions of TMP-SMX and emergence of TMP-SMX-resistant PJP, an individualized risk-based prophylaxis may be a more rational approach.
Here, to establish a patient-centred PJP prophylaxis protocol based on individual risk after renal transplantation, we evaluated the risk factors of PJP development at different post-transplantation periods. Furthermore, to correctly evaluate the limitation of current PJP prophylaxis protocol, we investigated the incidence and risk factors of adverse reactions causing premature TMP-SMX discontinuation and proposed a selective protocol based on the risk factors of PJP at different time points. 
MATERIALS AND METHODS

Study population and design
PJP prophylaxis and diagnosis
From 2011 to 2015, PJP prophylaxis for renal transplant patients was not a routine practice in our centre. Although routine prophylaxis after renal transplantation was recommended worldwide, agreement on its implementation was not reached in our centre due to the drug's frequent adverse reactions. During the study period, PJP prophylaxis was administered according to the preference of the primary physician. For those with prophylaxis, patients were started on daily low-dose oral TMP-SMX (80 mg TMP/400 mg SMX) within 1 month after kidney transplantation. The prophylaxis was continued for 6 months. Second line agents were not an option in our institution during the study period, because of its high cost (pentamidine) or unavailability (dapsone and meprone).
PJP diagnosis was based on clinical symptoms (fever, non-productive cough, shortness of breath, or night sweats), characteristic features on chest computed tomography (patchy ground glass opacity), and microbiologic confirmation.
Microbiologic diagnosis was made by identifying the organism, P. jirovecii, in respiratory samples (sputum, trans-tracheal aspirate, or bronchioalveolar lavage fluid) through immunofluorescent staining or detection of P. jirovecii DNA through polymerase chain reaction.
Immunosuppressive regimen
During the study period, most of the recipients received basiliximab as the induction therapy. In selected immunologically high-risk patients with panel reactive antibody (PRA) over 80% or high mean fluorescence intensity (MFI) of donor specific antibody (DSA), antithymocyte globulin (ATG) was administered instead.
After renal transplantation, patients were maintained on triple immunosuppressive regimen consisting of tacrolimus, mycophenolate mofetil or mycophenolic acid, and steroids.
Tacrolimus was administered twice a day, with an initial dose of 0.075 mg/kg and adjusted according to the daily serum concentration thereafter. The target trough level of tacrolimus was 10 to 12 ng/mL during the first 3 months post-operation, 8 to 10 ng/mL until 6 months, 6 to 8 ng/mL until 12 months, and 4 to 6 ng/mL thereafter. Mycophenolate mofetil or mycophenolic acid was administered at fixed dosages (500 or 360 mg, respectively; two times a day). After intraoperatively administering 500-mg methylprednisolone, steroid was rapidly tapered from 1 mg/kg/day methylprednisolone to 5 mg/day oral prednisone within 4 weeks. Acute rejection episodes were treated with 500 mg/day of methylprednisolone for 3 to 6 days and tapered afterwards.
In patients with acute T-cell mediated rejection where there was no clinical improvement with steroid therapy, 1.5 mg/kg/day of ATG was administered for up to 3 weeks. PJP prophylaxis was not administered during the steroid therapy, but was administered during ATG therapy. 
Data collection
Statistical analysis
Baseline demographic and transplant characteristics of the study population were analysed using descriptive statistics. 
RESULTS
Patient characteristics
In total, 578 renal transplant recipients were included, of which 241 (41.7%) were started on TMP-SMX within 1 month post-transplant to prevent PJP and 171 (29.6%; prophylaxis group) completed the 6-month prophylaxis course.
Patients who prematurely discontinued the drug (n=70, 57.5%).
Incidence and outcomes of PJP
Overall, there were 39 cases of PJP (six and 33 cases in the prophylaxis and no-prophylaxis groups, respectively) during a median follow-up of 51 months (interquartile range, 35.0 to 66.0) ( Fig. 1 
Incidence and risk factors of early PJP
The large difference in the incidence rate between the groups was due to the effective PJP prevention during the prophylaxis period in the prophylaxis group. Twenty-seven patients (6.6%) developed PJP within 6 months post-transplant in the no-prophylaxis group, whereas the prophylaxis group had none. The first case of early PJP documented oc- P=0.04) as significant predictive factors of subsequent early PJP. Table 1 ). When simulated with the data from the no-prophylaxis group, the proposed strategy will reduce the number of patients with unnecessary prophylaxis (93% to 34%) compared to the universal prophylaxis strategy, but would result in 2.2% residual incidence of early PJP.
Incidence and risk factors of late PJP
Six patients each from the prophylaxis and no-prophy-laxis groups developed PJP at 6 months post-transplant. The rate of late PJP was higher in the prophylaxis group (3.5% vs.
1.5%), but without statistical difference ( Table 4) P=0.04) were significantly associated with late PJP.
6. Estimated efficacy of the risk-based prophylaxis strategy to prevent late PJP Several prophylaxis strategies to prevent late PJP are proposed based on risk factors (Supplementary Table 2 ).
Theoretically, extended prophylaxis in patients aged ≥57 years and transplant from deceased donor would prevent 67% of the late PJP cases, resulting in the residual incidence of 0.7%. PJP risk in the proposed patient group for whom prophylaxis is indicated would be 10.3%, and the number required to treat to prevent one case would be 9.5. The cut-off age of 57 years was derived from the ROC curve analysis ( Supplementary Fig. 1 ).
Adverse reaction related to TMP-SMX prophylaxis
TMP-SMX prophylaxis were prematurely discontinued in Table 3 ). Generally, universal prophylaxis is recommended in patient groups with PJP incidence of more than 3% to 5% (12) .
DISCUSSION
Cumulative rate of early PJP in our patients undergoing contemporary immunosuppressive therapy was 6.1% without prophylaxis. PJP prophylaxis with TMP-SMX was highly effective; thus, none had early infection in the prophylaxis group. However, we frequently encountered TMP-SMX-as- (20) . Other changes in T-cell function may also contribute to increased risks of infection in the elderly (21) .
In contrast, donor source is rarely linked to PJP. One explanation for the increased risk of late PJP in deceased donor transplant compared to living donor transplant would be the higher burden of cumulative immunosuppression due to higher number of acute rejection and delayed graft function; however, this needs to be evaluated in further studies.
Additionally, the CMV infection is a factor that deserves mention. The association between CMV infection and PJP has been frequently demonstrated elsewhere (8, 18, 19) , suggesting that immune-modulating functions of CMV may have a role in PJP. We also observed a high rate of concurrent CMV and PJP infection that was frequently observed in our study population ( Supplementary Fig. 2 ). The CMV infection was also associated with late PJP when a COX regression analysis was performed, with the CMV infection as a fixed covariate. However, the association was not significant when the CMV infection was treated as a time-dependent covariate. Our data suggest that CMV is not a risk factor for subsequent PJP, and thus does not necessarily predict subsequent PJP. It is more likely that both CMV and PJP reflect a high degree of immunosuppression.
We months universal prophylaxis and extended selective prophylaxis in ＞55 years of age or those with rejection as an optimal prophylaxis strategy. Our study differ in that we have separately evaluated the risk factors of PJP at different time points after transplantation, and in that we have incorporated those with PJP prophylaxis in the analysis for the late PJP. Regardless of the difference, de Boer et al. (11) and our study group have reached a similar prophylactic strategy.
While we started this study to propose a selective prophylaxis strategy during the first 6 months because of the high rate of adverse event, we were unable to define a group of patients whose risk of PJP was low enough that PJP prophylaxis during the first 6 months could be safely avoided.
As PJP prophylaxis in the early transplant period seems unavoidable, future studies on less toxic prophylactic agent, as well as the accurate diagnosis and strategical management of TMP-SMX related adverse reaction are warranted.
The current study has several limitations, including the inherent limitation owing to its non-randomized retrospective single-centre design. The prophylaxis and no-prophylaxis groups were not randomly selected, and the two groups differed significantly in several baseline clinicopathologic properties. As prophylaxis virtually eliminated early PJP in the prophylaxis group, the risk factors of early PJP were evaluated only in the no-prophylaxis group.
Although the incidence of early PJP was not associated with the factors that differed between the two groups, such difference should be taken into account when interpreting and applying our results. The overall incidence of PJP was high (6.6%) and generally, may not be applicable in centers with a lower incidence rate. While this was mainly due to the high rate of early PJP caused by the lack of prophylaxis, considering that the rate of late PJP in the prophylaxis group (2.2%) was higher compared with Western countries, who showed an incidence rate of 0.3% to 1.8% after prophylaxis (8, 19, 22) , there is also a possibility that the inherent rate of PJP in our center is high. Because the net effect of a prophylaxis strategy depends greatly on the incidence of infection, antimicrobial resistance profile of the organism, and drug-tolerability of the target population, local characteristics should be considered before generalizing the results of our study. Last, as we did not have a common protocol on the indication of prophylaxis and management of adverse events during the study period, the decision to start or stop prophylaxis was left to the treating physician, and thus, may have been biased by individual preferences.
Without definite criteria of a renal adverse event (i.e., degree of rise in creatinine increase), and when to stop prophylaxis, we may have overestimated the rate of renal adverse events. 
CONCLUSION
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